Abstract
Hypothesis/Introduction
The renin-angiotensin system plays a central role in renal ischemia-reperfusion injury (IRI). We evaluated the effects of angiotensin-converting enzyme inhibitors (ACEIs) and AT1 receptor blockers (ARBs) in preclinical renal IRI models using multilevel and network meta-analyses (PROSPERO: CRD42024599859).
Materials and Methods
Database searches identified 55 studies. Serum creatinine data were pooled using three-level random-effects models (96 comparisons, n = 1233 animals). Publication bias was assessed using Egger and 1/√n methods. Drugs were ranked via P-scores.
Results
ACEIs/ARBs significantly reduced creatinine (standardized mean difference: −1.74; 95% CI: −2.22 to −1.26; p < 0.0001) with high heterogeneity. Egger's test showed asymmetry (p < 0.0001), but 1/√n-based testing did not (p = 0.160), suggesting mathematical artifact rather than publication bias. Multivariable meta-regression identified drug identity, dose, and route as key effect modifiers. Network analysis ranked azilsartan and telmisartan highest, though evidence remains limited (no direct comparisons, n = 2 for azilsartan). Secondary outcomes confirmed renal protection.
Conclusions
ACEIs/ARBs effectively reduce renal IRI in animals, with azilsartan and telmisartan ranking favorably despite limited evidence. High-dose intravenous administration enhances efficacy. Most studies used pre-ischemia protocols relevant only to transplantation. Post-injury models with comorbid animals of both sexes and direct drug comparisons are needed for clinical translation.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
